Filippo Cademartiri: Plaque Burden Is the Dominant Determinant of Long-Term Coronary Risk Beyond Stenosis
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn about a recent article by Ruurt A. Jukema et al, adding:
“Stenosis vs Plaque: We’ve been looking at the wrong winner.
Tackling stenosis above all does not make biological sense.
This study tackles a fundamental question in coronary artery disease:
- What really predicts outcomes over time?
- Is it how narrow the artery is… or how much disease is actually there?
Key message
The prognostic value of coronary disease is not static.
Early on: stenosis matters (flow limitation drives events)
Over time: plaque burden becomes dominant
Translation:
The more disease you carry, the more it matters than how tight a single lesion looks.
Why this is disruptive
For decades, cardiology has been built around:
- % stenosis
- ischemia
- revascularization decisions
But this paper reinforces something deeper:
Atherosclerosis is a diffuse, dynamic disease — not a focal narrowing problem.
The real shift
Plaque burden is:
- More stable as a biomarker
- More reflective of total disease biology
- More predictive in the long term
While stenosis?
- Fluctuates
- Is lesion-specific
- May miss the bigger picture
Clinical implications
If you focus only on stenosis:
- You treat lesions.
If you focus on plaque burden:
- You treat the disease.
That’s a completely different strategy.
Bottom line
We are moving from:
‘How tight is the blockage?’
to
‘How much disease is there overall?’
And that shift changes everything:
- Risk stratification
- Treatment intensity
- Prevention strategies
Final thought
- The artery doesn’t fail because of one stenosis.
- It fails because of the total plaque ecosystem.
And that’s where the future of imaging – and cardiology – is heading.”
Title: The time-varying prognostic value of stenosis and plaque burden in coronary artery disease
Authors: Ruurt A. Jukema, Teemu Maaniitty, Nick S. Nurmohamed, Pieter G. Raijmakers, Roel Hoek, Roel S. Driessen, R. Nils Planken, Jos Twisk, Pim van der Harst, Maarten J. Cramer, Antti Saraste, Paul Knaapen, Juhani Knuuti, Ibrahim Danad

Stay updated on all scientific advances with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF